Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.65 |
| ▸ | NPC1 | O15118 | 7/20 | 0.65 |
| ▸ | RAB9A | P51151 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | HTT | P42858 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28385558 | 0.91 | KMT2A (0.69) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL2834801 | 0.87 | PARP10 (0.59) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL23069072 | 0.84 | KMT2A (0.65) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL21810511 | 0.84 | KMT2A (0.73) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL11124086 | 0.82 | BCL2L1 (0.55) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL4911144 | 0.81 | MAPT (0.66) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL2464842 | 0.80 | KMT2A (0.65) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL21810505 | 0.80 | EPHX2 (0.65) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL29771005 | 0.80 | EPHX2 (0.65) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL11056635 | 0.80 | SMN1; SMN2 (0.74) | MEN1KMT2ANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | claimed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | claimed |
| EP-1786422-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | Prosidion Limited (GB) | 2007-05-23 | — | — | EP | claimed |
| WO-2006018662-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | PROSIDION LIMITED (GB) | 2006-02-23 | — | — | WO | claimed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1786422-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | Prosidion Limited (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006018662-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | PROSIDION LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | MEN1 4843/4885KMT2A 1905/4885NPC1 148/4885 |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | MEN1 4843/4885KMT2A 1905/4885NPC1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.